Safety and Performance of a GLOBAL Mapping and Ablation Device for the Treatment of Atrial Fibrillation (GLOBAL-AF)
Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
|3||Active, not recruiting||
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
† Study has passed its completion date and status has not been verified in more than two years.